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Aryl hydrocarbon receptor is required for optimal
B-cell proliferation
Matteo Villa1, Manolis Gialitakis1, Mauro Tolaini1, Helena Ahlfors1,†, Colin J Henderson2,
C Roland Wolf2, Robert Brink3 & Brigitta Stockinger1,*
Abstract
The aryl hydrocarbon receptor (AhR), a transcription factor known
for mediating xenobiotic toxicity, is expressed in B cells, which are
known targets for environmental pollutants. However, it is unclear
what the physiological functions of AhR in B cells are. We show
here that expression of Ahr in B cells is up-regulated upon B-cell
receptor (BCR) engagement and IL-4 treatment. Addition of a natu-
ral ligand of AhR, FICZ, induces AhR translocation to the nucleus
and transcription of the AhR target gene Cyp1a1, showing that the
AhR pathway is functional in B cells. AhR-deficient (Ahr/) B cells
proliferate less than AhR-sufficient (Ahr+/+) cells following in vitro
BCR stimulation and in vivo adoptive transfer models confirmed
that Ahr/ B cells are outcompeted by Ahr+/+ cells. Transcriptome
comparison of AhR-deficient and AhR-sufficient B cells identified
cyclin O (Ccno), a direct target of AhR, as a top candidate affected
by AhR deficiency.
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Introduction
The aryl hydrocarbon receptor (AhR), a ligand-dependent transcrip-
tion factor that responds to environmental signals, is widely
expressed in the haematopoietic system. As the AhR had originally
been defined as the receptor for dioxins and other chemical pollu-
tants, the effect of those substances on the development and func-
tion of immune cells was a focus in toxicological research for many
years (Kerkvliet, 2002). However, more recently the emphasis
shifted towards attempts to delineate the physiological functions of
AhR, which are indicated by its strong evolutionary conservation
from invertebrate onwards (Hahn et al, 1997). These studies were
facilitated by the availability of AhR-deficient mice (Fernandez-
Salguero et al, 1995; Schmidt et al, 1996; Mimura et al, 1997).
Although such mice exhibit no overt immunological phenotype in
steady state, alterations in immune responses and cell types are
revealed upon immunological challenge, indicating a substantial, if
currently insufficiently characterized role for AhR in many cell types
of the immune system, reviewed in (Stockinger et al, 2014). In B
cells, AhR is widely expressed in developmental subsets and upon
activation (Marcus et al, 1998; Tanaka et al, 2005; Sherr & Monti,
2013), and AhR engagement by environmental toxins was shown to
lead to suppression of humoral immune responses (Kerkvliet et al,
1990).
However, the physiological importance of AhR expression in B
cells remains ill defined. Here, we investigated the impact of AhR
deficiency on B-cell function in the absence of xenobiotic
influences.
We generated mice with B cell-specific deletion of Ahr via the
Cre-loxP system. AhR deficiency had no influence on B-cell
responses to T-dependent and T-independent antigens. However,
AhR-deficient B cells exhibited reduced ability to proliferate, being
less prone to enter the S phase of the cell cycle. As a consequence,
Ahr/ B cells were unable to compete with Ahr+/+ B cells and
were impaired in their ability to reconstitute an empty host or
mount an antigen-dependent proliferative response in vivo. Global
comparison of the transcriptome of AhR-deficient and AhR-sufficient
B cells identified cyclin O (Ccno) as one of the top candidates
affected by AhR deficiency, and ChIP analysis of the Ccno locus
showed it to be directly regulated by AhR.
Results
Expression of AhR in B cells is induced upon B-cell
receptor activation
Aryl hydrocarbon receptor expression in B cells has been previously
shown (Marcus et al, 1998; Tanaka et al, 2005), but these studies
did not explore the full repertoire of B-cell activation stimuli and
were largely based on using total splenocytes or cell lines. In order
to define the levels of Ahr expression in different developmental
subsets of B cells, we FACS purified B-cell subsets from bone
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marrow, spleen, peritoneal cavity and Peyer’s patches of non-
immune C57Bl/6 mice. Ahr was expressed across most subsets,
albeit at lower levels in bone marrow Pro and PreB cells and germi-
nal centre (GC) B cells. The highest expression was found in splenic
marginal zone B cells (MZB), peritoneal CD5+ B1 cells and bone
marrow-resident plasma cells (PCs) (Figs 1A and EV1A). The
expression levels of Ahr in total spleen B220+ B cells were similar
to that of TH17 cells (Fig EV1B) and among splenic subsets MZB
cells expressed the highest levels of Ahr (Fig EV1C). Activation of B
cells through the BCR, and to some degree with IL-4, resulted in
substantial up-regulation of Ahr, whereas TLR ligands such as LPS
or CpG as well as CD40 ligand and BAFF did not affect Ahr levels
(Fig 1B). We further explored whether BCR crosslinking and IL-4
could synergize in inducing Ahr expression. As shown in Fig 1C–E,
co-stimulation of B cells with anti-IgM and IL-4 substantially
increased AhR mRNA and protein expression as compared to the
single treatments. The increase in Ahr expression upon BCR stimu-
lation with anti-IgM (a-IgM) was seen across all subsets of splenic B
cells (Fig 1F). AhR expression peaked after 4 h of stimulation with
anti-IgM and IL-4 and steadily decreased over time approaching
steady-state levels by 24 h (Fig 1G).
Regulation of Ahr expression had previously been linked to the
canonical NF-jB pathway, albeit in mouse embryonic fibroblasts
(Vogel et al, 2014). We assessed the potential contribution of this
pathway in our system using the IKKb inhibitor BI605906, which
blocks the degradation of IjBa, thereby preventing nuclear
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Figure 1. B-cell activation via BCR engagement and/or IL-4 up-regulates Ahr expression.
A qPCR analysis of Ahr expression in B-cell subsets purified from C57Bl/6 mice. Ahr expression was normalized to Hprt1. n = 3–5 independent experiments; mean  SD.
B qPCR analysis of Ahr expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for 4 h as indicated. Ahr expression was normalized to Hprt1. Ahr
expression among groups was normalized to medium. n = 4 independent experiments; mean  SEM; one-way ANOVA, Dunnett’s multiple comparison test.
C qPCR analysis of Ahr expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for 4 h with 20 ng/ml IL-4 and/or 10 lg/ml a-IgM. Ahr expression was
normalized to Hprt1. Ahr expression among groups was normalized to medium. n = 3 independent experiments; mean  SEM; one-way ANOVA, Tukey’s multiple
comparison test.
D Western blot of protein extracts from splenic CD19+ cells isolated from C57Bl/6 mice and cultured for 4 h with 20 ng/ml IL-4 and/or 10 lg/ml a-IgM. Values above
the blots indicate AhR protein quantification obtained by densitometry, normalized to b-actin and compared to medium sample. Samples A and B indicate two
independent replicates.
E Quantification by densitometric analysis of the results shown in (D). n = 2 independent experiments; mean  range.
F qPCR analysis of Ahr expression in purified splenic B-cell subsets isolated from C57Bl/6 mice and cultured as indicated for 4 h. Ahr expression was normalized to
Hprt1. n = 2 independent experiments; mean  range.
G qPCR analysis of Ahr expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for the indicated time points with 20 ng/ml IL-4 and/or 10 lg/ml
a-IgM. Ahr expression was normalized to Hprt1. Ahr expression among groups was normalized to medium. n = 5 independent experiments; mean  SEM; one-way
ANOVA, Dunnett’s multiple comparison test.
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translocation of NF-jB. However, inhibition of NF-jB did not influ-
ence Ahr up-regulation upon BCR stimulation (Fig EV1D–F). AhR is
therefore expressed in steady-state B cell and further induced upon
engagement of the BCR in an NF-jB-independent fashion.
Nuclear translocation and activation of AhR in B cells
We next determined the translocation of AhR from its cytoplasmic
localization to the nucleus following exposure to ligand. Western
blot analysis of cytoplasmic and nuclear fractions of a-IgM-activated
B cells exposed to either the vehicle control DMSO, the high-affinity
endogenous ligand FICZ or the AhR inhibitor CH223191 showed
increased nuclear translocation upon exposure to FICZ, although
there was some nuclear AhR detectable in the control samples too
(Fig 2A). This could be due to the presence of tryptophan in culture
medium that is rapidly metabolized to form the AhR ligand FICZ
(Veldhoen et al, 2009); however, we cannot exclude also a direct
effect of DMSO in driving AhR translocation into the nucleus. In
contrast, the presence of the AhR inhibitor reduced nuclear translo-
cation, also compared to the DMSO control.
As a consequence of nuclear translocation following AhR activa-
tion, the downstream target Cyp1a1 was induced (Fig 2B). This
required both activation and exposure to AhR agonist and was
restricted to activation via the B-cell receptor. Although IL-4 treat-
ment of B cells increased their expression of Ahr, IL-4 in conjunction
with FICZ did not activate the AhR pathway and therefore did not
result in induction of Cyp1a1. In order to investigate AhR activation
in B cells on the single cell level, we took advantage of a mouse
model in which AhR activation can be traced by expression of a
reporter gene. This knock-in mouse strain bears a gene encoding
Cre recombinase under control of the endogenous Cyp1a1 promoter
(Henderson et al, 2015). Breeding these mice with reporter mice
expressing eYFP from the Rosa26 promoter allowed visualizing cells
that had activated the AhR pathway via eYFP expression.
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Figure 2. AhR translocates to the nucleus and induces Cyp1a1 expression upon BCR engagement and in the presence of FICZ in vitro.
A Western blot of nuclear and cytoplasmic protein extracts from splenic CD19+ cells isolated from C57Bl/6 mice and cultured with anti-IgM (a-IgM) for 4 h, followed by
the indicated treatment for 2 h. Values above the blots indicate AhR protein quantification obtained by densitometry, normalized to Sam68 or tubulin and compared
to the DMSO-treated sample. Representative data of n = 3 independent experiments.
B qPCR analysis of Cyp1a1 expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for 24 h as indicated. Cyp1a1 expression was normalized to Hprt1.
Cyp1a1 expression among groups was normalized to medium DMSO. n = 2 independent experiments; mean  range.
C Flow cytometry analysis of Cyp1a1 expression, reported by eYFP, in splenic CD19+ cells isolated from Cyp1a1Cre R26R eYFP mice and cultured for 72 h as indicated.
Representative data of n = 3 independent experiments.
D qPCR analysis of Cyp1a1 expression in purified splenic B-cell subsets isolated from C57Bl/6 mice and cultured as indicated for 24 h. Cyp1a1 expression was
normalized to Hprt1. n = 2 independent experiments; mean  range.
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As shown in Fig 2C, B cells from Cyp1a1Cre reporter mice,
cultured either without stimulation (medium), with IL-4 or with the
combination of IL-4 and a-IgM showed increased eYFP expression
upon BCR stimulation, already under baseline conditions without
addition of AhR agonist. Addition of FICZ markedly increased eYFP
expression in a-IgM-stimulated cells, whereas addition of the AhR
antagonist CH223191 reduced the background levels of eYFP (which
are due to AhR agonists in the medium) and also suppressed eYFP
expression in stimulated B cells. Optimal induction of Cyp1a1
expression was dependent on both B-cell receptor triggering and
presence of AhR ligand and was observed across all mature B-cell
subsets in the spleen (Fig 2D).
Thus, mature B cells in peripheral lymphoid organs express AhR
and respond to AhR ligands by AhR translocation to the nucleus
and activation of the classical AhR pathway that results in induction
of Cyp1a1.
Activation of antigen-specific B cells induces the AhR
pathway in vivo
In order to investigate whether AhR is functionally active in B cells
in vivo, we crossed the Cyp1a1Cre reporter mice to transgenic mice
expressing a hen egg lysozyme (HEL)-specific BCR (SWHEL mice)
(Phan et al, 2003). In SWHEL mice, 40–60% of B cells respond to
HEL and these B cells are able to undergo class switching. We trans-
ferred total splenocytes from CD45.1 allotype-marked SWHEL
Cyp1a1Cre mice together with sheep red blood cells (SRBCs) coupled
with HEL or mock-coupled into C57Bl/6 recipients to induce a T
cell-dependent response of HEL-specific B cells. In addition, some of
the mice received injection of the xenobiotic AhR ligand 3-methyl-
cholanthrene (3-MC), since FICZ is rapidly metabolized in vivo
(Fig 3A). Seven days later, eYFP expression in GC and non-GC B
cells isolated from the spleens of recipient mice was analysed. Upon
immunization with SRBC-HEL, the transferred B cells expanded and
formed GC (Fig 3B middle and lower rows), whereas mice treated
with SRBC-mock had no detectable donor-derived GC B cells
and even in the presence of 3-MC failed to show induction of
Cyp1a1 (measured as eYFP, Fig 3B top row). Mice that received
SRBC-HEL together with vehicle showed GC B-cell expansion, but no
up-regulation of Cyp1a1. Only the combination of antigen-dependent
activation and AhR agonist was able to drive Cyp1a1 expression in
both GC and non-GC B cells (Fig 3B bottom row, Fig 3C and D).
This suggests that antigen stimulation of BCR, by inducing AhR
expression, enhances the sensitivity of AhR pathway to available
ligands and it is in line with the absence of eYFP expression in
untreated Cyp1a1Cre reporter mice.
AhR deficiency impairs B-cell proliferation in vitro and in vivo
In order to evaluate the consequences of AhR deficiency in B cells,
we established mice that specifically lack AhR in B cells by crossing
Ahr+/+ or Ahr/ mb1Cre mice with Ahrfl/fl mice to generate Ahrfl/+
mb1Cre+ controls and Ahrfl/ mb1Cre+ offspring (Fig EV2A). mb1Cre
mice carry a construct for Cre recombinase under the control of the
B cell-specific mb1 promoter (mb1 encodes for Iga/CD79A, an
essential signalling component of the BCR complex; Hobeika et al,
2006). The mice we generated also express a Cre-dependent reporter
that marks cells as eYFP+ upon Cre recombinase activation
(Fig EV2A). Cre-induced deletion of Ahr, as well as eYFP fate-
reporting, was efficient and specific, from the earliest stages of B-cell
development in the bone marrow (c-kitint B220+ cells) to the periph-
eral compartment (Fig EV2B–E). We assessed the composition of
the B-cell compartment and serum immunoglobulin levels at steady
state in Ahrfl/ mb1Cre+ and Ahrfl/+ mb1Cre+ non-immune mice and
compared them to mice with complete deletion of AhR (Ahr/). B
cell-specific AhR-deficient mice and full Ahr/ mice showed no
major differences in the distribution of B-cell subsets (Fig EV3A and
Appendix Fig S1A). However, full Ahr/ mice had altered serum
immunoglobulin levels as compared to Ahr+/+ controls, showing
elevated IgM but reduced IgG1 isotypes (Appendix Fig S1B and C),
whereas other isotypes were expressed to similar levels
(Appendix Fig S1D–G). In contrast, there were no differences in the
serum immunoglobulin levels between Ahrfl/ mb1Cre+ and Ahrfl/+
mb1Cre+ mice (Fig EV3B–G). Responses to immunization with
T-independent (TNP-Ficoll) and T-dependent (NP-CGG and cholera
toxin—Ctx) antigens resulted in similar antibody responses in mice
with AhR-deficient or AhR-sufficient B cells (Fig EV4).
However, it was noticeable that AhR-deficient B cells (Fig 4A,
black line) were compromised in their proliferative potential follow-
ing BCR stimulation, compared with AhR-sufficient B cells (Fig 4A,
solid grey). B cells from heterozygous Ahr+/ mice showed similar
reduced proliferation in the presence of the AhR antagonist
CH223191 (Fig 4A, red line). This reduced proliferation was
reflected in a decrease in dilution of the cell division tracer CTV dye
(Fig 4A), reduced expansion index (Fig 4B), and a reduction in the
percentage of divided cells (Fig 4C), while the replication index was
similar (Fig 4D), indicating that those Ahr/ B cells that entered
division proceeded through the cell cycle like AhR-sufficient cells.
The delay in cell cycle progression was caused by increased reten-
tion in G0/G1 phase of AhR-deficient B cells (Fig 4E). We further
tested whether AhR deficiency causes apoptosis in B cells cultured
for 72 h in medium or IL-4 by staining for annexin-V, but there was
no evidence that the reduced expansion of AhR-deficient B cells was
linked to apoptosis (Appendix Fig S2).
In order to determine the in vivo consequences of impaired
proliferation in AhR-deficient B cells, we generated mixed bone
marrow chimeras transferring equal numbers of bone marrow cells
from Ahrfl/ mb1Cre+ mice together with Ahrfl/+ mb1Cre+ bone
marrow (distinguishable by expression of different fluorochromes in
the Rosa26 locus), into irradiated Rag1/ hosts. The relative contri-
bution of AhR-deficient B cells (white) vs. AhR-sufficient B cells
(black) to the B-cell pool was determined 8 weeks later. As shown
in Fig 5A and B, the composition of the mature B-cell pool was
substantially skewed in favour of B cells that originated from
Ahrfl/+ mb1Cre+ bone marrow, whereas bone marrow-resident
immature subsets of B cells did not show this trend.
To test whether AhR regulates proliferation in response to anti-
genic stimulation, we co-transferred splenocytes from SWHEL Ahr
/
and SWHEL Ahr
+/+ mice (distinguishable by CD45 allotype expres-
sion) into C57Bl/6 CD45.1+ hosts together with SRBC-HEL (Fig 5C).
7 days later, the distribution of HEL-specific AhR-deficient and AhR-
sufficient B cells in the spleen of recipient mice was analysed. Immu-
nization with SRBC-HEL caused expansion of both Ahr+/+ (black,
CD45.1+ CD45.2+) and Ahr/ (white, CD45.2+) B cells compared
to the mock immunized controls (Fig 5D). However, AhR-sufficient
B cells expanded more than AhR-deficient B cells so that over 60%
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of the HEL-specific B cells detected in the recipient mice originated
from the AhR-sufficient input, whereas AhR-deficient B cells only
represented less than 40% of the HEL-specific B-cell pool (Fig 5E).
This confirmed that AhR-deficient B cells are less prone to prolif-
erate in response to BCR engagement and lose out in competition
with AhR-sufficient B cells.
To test whether the reduced proliferation potential of Ahr/ B
cells has further functional consequences in vivo, we tested whether
AhR deficiency had an impact on the generation of short-lived
splenic and long-lived bone marrow plasma cells (PCs) in non-
immune mice. Ahrfl/ mb1Cre+ mice showed a reduced number of
PCs in the spleen as compared to AhR-sufficient controls
(Appendix Fig S3A and B). On the other hand, in the bone marrow
long-lived PCs were represented in similar numbers in Ahrfl/
mb1Cre+ mice compared with Ahrfl/+ mb1Cre+ mice (Appendix Fig
S3C and D). Immunization with NP-CGG, however, did not reveal
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Figure 3. B-cell activation in the presence of 3-MC promotes Cyp1a1 transcription in vivo.
A Host C57Bl/6 mice were injected with CD45.1+ splenocytes, isolated from SWHEL × Cyp1a1
Cre R26R eYFP mice together with SRBC-HEL or SBRC-mock. The
transferred mice were treated with 3-MC or vehicle. Readout at d7 post-challenge was eYFP expression in transferred CD45.1+ cells.
B Representative flow cytometry analysis of Cyp1a1 expression, reported by eYFP, in CD45.1+ cells harvested from mice challenged as in (A). Gating is indicated above
the plots. Representative data of n = 3 independent experiments. GC cells: CD95+ GL-7+; non-GC cells: CD95 GL-7.
C, D Summary of percentage of GC (C) and non-GC eYFP+ (D) cells from flow cytometry analysis. n = 3 independent experiments; lines indicate mean; one-way ANOVA,
Tukey’s multiple comparison test.
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any difference between splenic PC numbers of Ahrfl/ mb1Cre+ mice
compared with Ahrfl/+ mb1Cre+ mice. This might indicate that the
partial proliferative defect can eventually be corrected provided there
are not wild-type competitor B cells around (Appendix Fig S3E).
We next determined whether AhR deficiency in B cells influences
the generation of high-affinity antibodies in vivo. For this, we co-
transferred in a 1:1 ratio splenocytes from SWHEL mice, which were
either AhR-deficient (white) or AhR-sufficient (black). The hosts
were immunized with SRBC coupled with a modified HEL protein
carrying three point mutations (HEL3x), for which the SWHEL B-cell
receptor has 10,000-fold lower affinity compared with unmodified
HEL (Fig EV5A). Therefore, only B cells that have undergone affin-
ity maturation in GC are able to bind HEL3x (Paus et al, 2006). AhR
deficiency did not compromise the intrinsic ability to undergo
affinity maturation as suggested by the similar proportions of
HEL3x-binding IgG1+ or IgG1 B cells between the two genotypes
(Figs 5F and EV5B). Nevertheless, when total numbers of B cells
that underwent affinity maturation were taken into consideration,
both IgG1+ and IgG1 HEL3x-binding B cells from AhR-deficient
hosts were substantially reduced compared with their AhR-sufficient
counterpart, likely due to their reduced expansion potential
(Fig 5G).
Thus, AhR deficiency impairs antigen-dependent B-cell prolifera-
tion and the generation of high-affinity antibodies in vivo, without
compromising the process of affinity maturation itself.
Cyclin O is defective in AhR-deficient B cells
A role for AhR in the regulation of the cell cycle has been described
before, albeit in cell lines, and the suggestion was that induction of
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Figure 4. AhR deficiency impairs B-cell proliferation in vitro.
A Flow cytometry analysis of CTV dilution in splenic CD19+ cells sorted from non-immune Ahrfl/+ mb1Cre+ (Ahr+/ B cells, solid grey) and Ahrfl/ mb1Cre+ (Ahr/ B cells,
black) mice stimulated for 72 h as indicated. Treatment of Ahr+/ CD19+ cells with CH223191 is indicated in red. Representative data of n = 4–5 independent
experiments.
B–D Flow cytometry analysis of expansion index (B), % of divided cells (C) and replication index (D) of splenic CD19+ cells sorted from non-immune Ahrfl/+ mb1Cre+
(black) and Ahrfl/ mb1Cre+ (white) mice stimulated for 72 h as indicated. Treatment of Ahr+/ CD19+ cells with CH223191 is indicated in red. n = 4–5 independent
experiments; mean  SEM; two-way ANOVA, Sidak’s multiple comparison test.
E Flow cytometry analysis of cell cycle distribution of splenic CD19+ cells purified from non-immune Ahrfl/+ mb1Cre+ (black) and Ahrfl/ mb1Cre+ (white) mice stimulated
for 48 h with 5 lg/ml a-IgM. Data representative of n = 2 independent experiments; lines indicate mean; two-way ANOVA, Sidak’s multiple comparison test.
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the cell cycle inhibitor p27kip1 underlies the G0/G1 cell cycle arrest
following dioxin treatment, whereas other studies described cell
cycle arrest in AhR-deficient cell types (Ma & Whitlock, 1996;
Elizondo et al, 2000; Levine-Fridman et al, 2004). We therefore
tested expression of p27kip1, expression of the activation markers
CD69, CD86 and MHC II, and calcium mobilization following activa-
tion of AhR-sufficient and AhR-deficient B cells with a-IgM. Ahr/
B cells did not show any alteration in p27Kip1 expression or
activation markers as compared to AhR-sufficient B cells upon BCR
engagement (Appendix Fig S4A–D) nor did they show altered
calcium mobilization (Appendix Fig S4E). Since AhR targets a large
number of genes, we performed an unbiased RNA sequencing
screen, comparing Ahr+/+ and Ahr/ B cells activated in vitro with
a-IgM and IL-4 in the presence of FICZ. Figure 6A and B, and
Appendix Tables S1 and S2 show the top 20 differentially regulated
genes upon deletion of Ahr. Differentially regulated genes were
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Figure 5. AhR deficiency impairs BCR-dependent B-cell proliferation in vivo.
A, B Flow cytometry analysis of distribution of CD45.1+ and CD45.2+ cells in indicated cell subsets purified from bone marrow (A) and lymph node (B) of sublethally
irradiated Rag1/ mice 8 weeks after reconstitution with equal numbers of bone marrow cells from Ahr+/+ (CD45.1+) and Ahr/ (CD45.2+) mice. Dashed lines
indicate 50% level. Representative data of n = 2 independent experiments; two-tailed paired t-test.
C Host CD45.1 mice were co-transferred with a 1:1 mixture of HEL-specific Ahr+/+ CD45.1+CD45.2+ splenocytes isolated from SWHEL Ahr
+/+ mice and HEL-specific
Ahr/ CD45.2+ splenocytes isolated from SWHEL Ahr
/ mice in the presence of SRBC-HEL or SRBC-mock. Readout at d7 post-challenge was distribution of Ahr+/+
CD45.1+CD45.2+ vs. Ahr/ CD45.2+ cells.
D Flow cytometry analysis of distribution of CD45.1+CD45.2+ and CD45.2+ cells harvested from host mice challenged as indicated above the dot plots. Representative
data of n = 3 independent experiments.
E Flow cytometry analysis of distribution of Ahr+/+ CD45.1+CD45.2+ (black) and Ahr/ CD45.2+ (white) cells harvested from host mice. Indicated distribution is
quantified relative to transferred cells. X symbols indicate SRBC-mock-treated control. Dashed line indicates 50% threshold. Representative data of n = 3
independent experiments; two-tailed paired t-test.
F, G Flow cytometry analysis of distribution (F) and cell numbers (G) of IgG1+ and IgG1 HEL3x-binding Ahr+/+ CD45.1+CD45.2+ (black) and Ahr/ CD45.2+ (white) cells
harvested from host mice. Representative data of n = 2 independent experiments; two-tailed paired t-test.
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Figure 6. AhR-deficient B cells fail to up-regulate Ccno expression.
A, B Tables showing the top 20 down-regulated (A) and up-regulated (B) genes in Ahr/ B cells as compared to Ahr+/+ cells, after analysis by RNA sequencing. B cells
were activated with 10 lg/ml a-IgM + 20 ng/ml IL-4 for 8 h; 250 nM FICZ was added to the culture during the last 4 h. The average read counts are directly
proportional to the extent of expression of a given gene in Ahr+/+ or Ahr/ cells. Data from n = 3 mice per group. Average read counts for the housekeeping gene
Hprt1 in both Ahr+/+ and Ahr/ B cells are indicated below the table in (A).
C qPCR analysis of Ccno expression in splenic CD19+ cells isolated from non-immune Ahrfl/+ mb1Cre+ (Ahr+/ B cells, black) and Ahrfl/ mb1Cre+ (Ahr/ B cells, white)
mice, stimulated with 10 lg/ml anti-IgM for the indicated time points. Ccno expression was normalized to Hprt1. n = 3 independent experiments; mean  SEM;
two-way ANOVA, Sidak’s multiple comparison test.
D qPCR analysis of Ccno expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for 8 h with 20 ng/ml IL-4 and/or 10 lg/ml a-IgM. Ccno expression
was normalized to Hprt1. n = 3 independent experiments; mean  SEM; one-way ANOVA, Tukey’s multiple comparison test.
E qPCR analysis of Ccno expression in splenic CD19+ cells isolated from C57Bl/6 mice and cultured for the indicated time points with 20 ng/ml IL-4 and/or 10 lg/ml
a-IgM in the presence or absence of 250 nM FICZ or 1 lM 3-MC. Ccno expression was normalized to Hprt1. n = 3 independent experiments; mean  SEM; one-
way ANOVA, Tukey’s multiple comparison test.
F Chromatin immunoprecipitation (ChIP) analysis of AhR interaction with the Ccno promoter and an irrelevant region (3.3 kb from Ccno transcription starting site)
in Ahr+/+ (black) and Ahr/ (white) B cells 5 h after activation with 10 lg/ml a-IgM + 20 ng/ml IL-4. 250 nM FICZ was added in the last hour of culture.
Representative data of n = 2 independent experiments; mean  SEM; two-way ANOVA, Sidak’s multiple comparison test.
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screened with gene ontology and pathway analysis tools. Apart from
the expected absence of the prototypical AhR target genes Cyp1a1,
Cyp1b1 and Ahrr, one of the most strongly down-regulated genes in
AhR-deficient B cells was Ccno, encoding cyclin O, a member of the
cyclin family. To confirm the RNA sequencing result and to dissect
the AhR dependency of Ccno expression dynamics in B cells, splenic
CD19+ B cells were isolated from Ahrfl/ mb1Cre+ and Ahrfl/+
mb1Cre+ mice, stimulated with a-IgM and Ccno expression was
assessed over a 24 h period. Ccno was maximally induced about 8 h
after stimulation in AhR-sufficient B cells, but not detectable in
AhR-deficient B cells, confirming the RNA sequencing result
(Fig 6C). Furthermore, Ccno expression was enhanced by concomi-
tant stimulation with anti-IgM and IL-4 presumably due to the
increased levels of AhR under these conditions (Fig 6D). This was
further enhanced in the presence of AhR ligands FICZ and 3-MC
(Fig 6E). ChIP PCR established that AhR directly bound to the Ccno
promoter to regulate its expression (Fig 6D).
Discussion
With the appreciation of physiological roles of the AhR beyond the
detoxification of environmental pollutants, immunologists are
increasingly focusing on the functions of this transcription factor in
different immune cell populations. We had initially described
expression of AhR in T cells, where it is confined to the TH17 cell
subset and required for the induction of interleukin 22 (Veldhoen
et al, 2008), but it appears that AhR is more widely expressed in
other immune cell types (Stockinger et al, 2014). B cells show
universal expression albeit at generally low levels, with the excep-
tion of subsets like MZB cells and B1 B cells. These subsets are
considered to be rapidly responsive to repetitive epitopes displayed
by environmental pathogens and self-antigens and may therefore be
in an elevated state of activation (Martin & Kearney, 2002;
Baumgarth, 2011). Since BCR activation results in up-regulation of
Ahr, it is likely that the increased Ahr expression in MZB and B1
cells mirrors their activation profile rather than representing a
characteristic feature. Furthermore, the ability to up-regulate Ahr
expression upon BCR activation applied to all splenic B-cell subsets,
confirming that Ahr up-regulation may reflect BCR engagement and
is not an exclusive feature of specific B-cell subsets. The link
between BCR engagement and Ahr induction is still unknown, but
does not involve the canonical NF-jB pathway in contrast to what
was recently postulated in fibroblasts (Vogel et al, 2014).
The role for AhR in B cells has been studied extensively in
the context of environmental chemical-mediated toxicity and
suppression of the humoral immune response by dioxin is a well-
established phenomenon, and exposure of primary B cells or B-cell
lines to chemical AhR ligands indicated a role in the control of B-cell
response acting at multiple levels (Sulentic & Kaminski, 2011; Sherr
& Monti, 2013). Our study of B-cell function in mice in which AhR
deficiency was targeted to B cells did not indicate any alterations in
B-cell responses against T-independent and T-dependent challenges.
However, upon closer scrutiny it was apparent that AhR-deficient
B cells had reduced proliferation potential due to their retention in
G0/G1 stage of the cell cycle. This defect was partial, as those B cells
that managed to overcome the block proliferated normally. Never-
theless, it was apparent that AhR-deficient B cells lost out in
competition with AhR-sufficient B cells, both in settings of homeo-
static proliferation (Fig 5A and B) and upon antigen-driven prolifer-
ation (Fig 5D and E). Interestingly, Ahr deletion did not impair the
ability of B cells to proliferate per se, but instead compromised their
likelihood to commence the cell cycle. Indeed, the reduced expan-
sion potential of Ahr/ B cells was mirrored by the reduced frac-
tion of cells undergoing cell division. On the other hand, the
replication index, indicating the proliferative capacity of cells that
already underwent division, was comparable between AhR-
sufficient and AhR-deficient B cells. These results suggest that AhR
could be a modulator of the B-cell activation threshold, augmenting
the sensitivity of B cells to BCR triggers.
B-cell proliferation is important to sustain the affinity maturation
process in GC that allows generation of high-affinity antibodies.
Recent studies showed that the magnitude of T cell help received by
GC B cells in the light zone is positively correlated with the division
rate and number of point mutations accumulated in immunoglobu-
lin genes in the dark zone (Victora et al, 2010; Gitlin et al, 2014). In
the SWHEL model, AhR deficiency did not impair the intrinsic ability
of B cells to undergo affinity maturation, since comparable fractions
of Ahr+/+ and Ahr/ B cells underwent affinity maturation and
bound HEL3x. However, because of the expansion defect of Ahr/
B cells as compared to Ahr+/+ controls, the total number of HEL3x-
binding affinity-matured AhR-deficient B cells was lower. Thus,
reduced expansion rather than an intrinsic affinity maturation defect
led to a reduced ability to generate high-affinity antibodies. These
data are in line with the finding that AhR deficiency impacts BCR-
driven proliferation, whereas T cell-driven B-cell proliferation that
occurs in GC during the affinity maturation process remains unaf-
fected. Indeed, we observed that stimuli other than through the
BCR, including CD40 ligation, did not have any effect on Ahr expres-
sion levels. Mice with AhR-deficient B cells also showed a defect in
short-lived plasma cells in the spleen, whereas long-lived plasma
cells in the bone marrow appeared normal, suggesting that over
time the reduced expansion due to problems of entering into the cell
cycle can be compensated.
Thus, it appears that endogenous AhR ligands play a role in
maintaining the functional response of B cells to antigen activation.
In order to detect AhR activation in vivo, we employed a fate
reporter mouse model in which mice with Cre recombinase inserted
under control of the endogenous Cyp1a1 promoter were crossed
with Rosa26 eYFP reporter mice such that cell that has activated the
AhR pathway and induced Cyp1a1 would be permanently labelled
with the eYFP fluorochrome (Henderson et al, 2015). Under steady-
state conditions, B cells of these mice did not express the reporter
and in general we found very low eYFP expression, mainly in non-
haematopoietic cells (M. Villa, unpublished observation). This is
most likely due to the tight regulation of AhR activation that is
subject to strong feedback control and therefore might not result in
sufficiently prolonged Cyp1a1 expression to turn on Cre recombi-
nase. However, deliberate addition of AhR agonists either in vitro or
together with immunization in vivo strongly induced this reporter,
confirming its functionality. It therefore seems that the AhR path-
way is functional in B cells in vivo, but exposure to endogenous
ligands was subthreshold of detection with the reporter.
Observations in the toxicology field have implicated AhR in cell
cycle regulation with different effects in different cell types (Puga
et al, 2002). Whereas transient AhR engagement in a hepatoma cell
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line promoted G0/G1 to S phase transition, sustained activation with
dioxin increased p27Kip1 expression, promoting cell cycle arrest
(Levine-Fridman et al, 2004). In contrast, other studies showed that
AhR deficiency negatively affected cell proliferation (Ma & Whitlock,
1996; Elizondo et al, 2000; Tohkin et al, 2000). It is possible that
prolonged AhR activation via dioxin that is not metabolized
might in some cases mimic AhR deficiency, presumably due to the
fact that this exposure can lead to profound down-regulation
and degradation of AhR (Pollenz et al, 1998). It is noteworthy that
AhR knockdown was recently shown to reduce expression of
E2F1, which is involved in regulation of cell cycle and apoptosis
(Frauenstein et al, 2013). These observations are difficult to extra-
polate to primary B cells and we did not observe any alteration in
p27kip1 levels in AhR-deficient B cells.
In order to understand the mechanistic basis for the defective
proliferation of AhR-deficient B cells, we carried out an unbiased
RNA sequencing screen comparing BCR-activated B cells from AhR-
deficient and AhR-sufficient mice. It should be noted that our screen
did not overlap with previous screens of dioxin-activated B-cell lines,
clearly indicating that the chemical activation of AhR interferes with
B-cell responses on a different level (De Abrew et al, 2010).
A top scoring differentially expressed gene, apart from AhR path-
way genes such as Cyp1a1 and Ahrr, was Ccno, encoding the cyclin
family member cyclin O, which seemed a plausible candidate to
explain the reduced proliferative potential of AhR-deficient B cells
and furthermore appears to be directly regulated by AhR as AhR
bound to the Ccno promoter.
Cyclin O was erroneously identified as a component of the
molecular complex involved in antibody class switch recombination
and affinity maturation (Muller & Caradonna, 1991). However, a
later report described a possible role for cyclin O in controlling cell
cycle, as it is expressed as a function of the cell cycle. Cyclin O
expression peaked during the G1 phase, while undergoing complete
turnover by the end of the cell cycle, an expression pattern typical
of cell cycle regulators (Muller & Caradonna, 1993). AhR-deficient B
cells failed to express Ccno, while it was transiently up-regulated in
Ahr+/+ B cells about 8 h after activation. Conservation analysis
between the human and mouse Ccno gene established the presence
of multiple dioxin response elements (DREs) within several regions
of the Ccno locus (Appendix Fig S5). Although the involvement of
Ccno in regulation of B-cell proliferation is so far not experimentally
proven, this molecule represents a potential candidate.
Thus, AhR sensing of endogenous ligands by B cells has a subtle,
but detectable influence on their physiology. As the exposure of B
cells to endogenous AhR ligands was not measurable using a
Cyp1a1 fate reporter, we can only infer a role for AhR signalling in
B cells through the deleterious effects of AhR deficiency. It is likely
that the transient nature of AhR signalling is of particular signifi-
cance for its physiological functions.
Materials and Methods
Mice and immunizations
C57BL/6J (in the text called C57Bl/6), B6.129S7-Rag1tm1Mom/J
(Rag1/), B6.129-Ahrtm1Bra/J (Ahr/), Cd79 atm1(cre)Reth (mb1Cre)
(Hobeika et al, 2006), Ahrtm3.1Bra/J R26R eYFP (Ahrfl/fl), Cyp1a1Cre
R26R eYFP (Henderson et al, 2015) and SWHEL mice (Phan et al,
2003) were bred and kept at Francis Crick Institute animal facilities
under specific pathogen-free conditions. Mice were used after
8 weeks of age, age- and gender-matched unless otherwise stated.
All animal experiments were performed according to institutional
guidelines (Francis Crick Institute Ethical Review Panel) and UK
Home Office regulations.
TNP-Ficoll (Biosearch Technologies; 10 lg/mouse in PBS) and
NP-CGG (Biosearch Technologies; 10 lg/mouse in PBS:Alum
(Thermo Scientific) 3:1) immunizations were done by intra-
peritoneal (i.p.) injection. For cholera toxin (Ctx; List Biological
Laboratories, Inc.) immunization, mice were starved for 2 h and
HBSS + 7.5% sodium bicarbonate solution (4:1 ratio) was adminis-
tered by intra-gastric (i.g.) gavage, followed 30 min later by i.g.
gavage of 2.5 lg active Ctx in PBS. Mice were culled at d14 post-
immunization for analysis.
SWHEL mice were used as donors of HEL-specific B cells that
were transferred into a naive congenic recipient mouse together
with HEL conjugated to the carrier SRBC to induce a T-dependent
response. Host and donor differed in the allotypic marker CD45,
which allowed assessment of donor-specific responses in an
immune-competent mouse (Phan et al, 2003).
Briefly, 50,000 HEL+ B cells were transferred together with 109
HEL-conjugated SRBC (SRBC-HEL) intravenously (iv) in PBS into
recipient mice. For each experiment, a mock control immunized
with uncoupled SRBC was used. Mice were analysed at d7 post-
immunization. In some experiments, the AhR ligand 3-MC (Sigma)
was dissolved in corn oil and injected ip at a concentration of
26.5 mg/kg. For conjugation, SRBCs (Patricell) were extensively
washed in PBS and resuspended in conjugation buffer (0.35 M
mannitol, 0.01 M NaCl). HEL (2 mg/ml; Sigma) or HEL3x (100 lg/
ml; kindly provided by R. Brink) was added 1:10 and incubated
10 min at 4°C. Without washing, EDCI (Novabiochem) 100 mg/ml
in conjugation buffer was added 1:10 and incubated 30 min at 4°C.
SRBCs were then extensively washed in PBS, counted and resus-
pended in PBS.
To generate bone marrow chimeras, lethally irradiated
(2 × 5 Gy) Rag1/ recipient mice (6–8 weeks old) received iv
transfer of bone marrow (BM) cells from gender-matched donors.
Recipient mice were kept under antibiotic treatment (Baytril 0.02%
in drinking water; Bayer) for 2 weeks. Blood samples were taken
4 weeks after reconstitution to check for chimerism, and recipient
mice were used for experiments not earlier than 8 weeks post-
reconstitution.
Flow cytometry
B-cell subsets were sorted or analysed as follows: from spleen: FoB
(B220/CD19+ CD93 IgM+ CD23+); MZB (B220/CD19+ CD93
IgMhi CD23); TrB (B220/CD19+ CD93+); PC (B220 CD138+). TrB
subsets were further separated on the basis of IgM and CD23 expres-
sion: T1 (IgM+ CD23), T2 (IgM+ CD23+) and T3 (IgMlo CD23+).
From bone marrow: ProB (B220+ CD2); PreB (B220+ CD2+ IgM
IgD); Immature B (B220+ CD2+ IgM+ IgD); Mature B (B220+
CD2+ IgM+ IgD+); PC (IgD B220 CD138+); Stem cells (B220
cKit+); Early ProB (cKitdim B220+); B-cell precursors (cKit B220+
CD19+); NK cell precursors (cKit B220+ CD19). From peri-
toneal cavity: CD5+ B1 (IgMhi CD23 CD5+); CD5 B1 (IgMhi,
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CD23 CD5) CD5 B1; B2 (IgM+ CD23+). From Peyer’s patches:
GC B (B220/CD19+ CD95+ GL-7+); non-GC B (B220/CD19+ CD95
GL-7); TFH (CD4
+ TCRb+ PD-1+ CXCR5+).
The following antibodies were used for flow cytometry: CD2,
CD4, CD5, CD19, CD23, CD45.1, CD45.2, CD69, CD86, B220, MHC
II, PD-1, TCRb (Biolegend); CD93 (clone AA4.1), cKit, GL-7, IgD
(eBioscience); CD95, CXCR5, IgG1, CD138 (clone 281-2) (BD Bio-
sciences); IgM (Jackson Immunores. Lab; Fab fragment).
Cell proliferation was quantified by flow cytometry using Cell-
TraceTM violet cell proliferation kit (Life Technologies). Cell prolifer-
ation parameters such as % of divided cells, expansion index and
proliferation index were obtained using the proliferation platform of
FlowJo software (version 9; Treestar). % of divided cells represents
the fraction of the initial population that underwent cell division.
Expansion index indicates the fold expansion of the overall culture.
Replication index indicates the fold expansion of only the respond-
ing cells.
Cell cycle stage was analysed by flow cytometry using Vybrant
DyeCycleTM violet stain (Life Technologies).
For calcium flux analysis, cells were incubated with Indo-1 AM
(Invitrogen) IMDM 5% FCS (final Indo-1 AM concentration 2 lM)
for 30 min at RT. Cells were washed and resuspended at a concen-
tration of 107 cells/ml in IMDM 5% FCS and kept at 37°C until
analysis. Cells were stimulated with anti-IgM at appropriate
concentrations. Calcium flux was quantified by measuring the ratio
between the violet and blue emission upon Indo-1 AM excitation by
UV laser.
Flow cytometric analysis was performed on BD FACS Canto II,
BD LSR II or BD LSRFortessa flow cytometers (BD Biosciences). Cell
sorting was performed on a BD FACSAria II, BD Influx (BD Bio-
sciences) or MoFlo XDP (Beckman Coulter). Data were analysed
using FlowJo software (Treestar).
Cell culture
Splenic B cells were purified using the EasySep mouse B-cell isola-
tion kit according to manufacturer instructions. Purity was assessed
by flow cytometry, and 90–95% of the purified cells were CD19+. Cells
were cultured at appropriate concentrations (i.e., 250,000 cells/well
in 200 ll in 96-well plates) in complete IMDM at 37°C, 7% CO2. Cells
were treated with a-IgM, concentrations between 10 and 1.25 lg/ml
(Fab fragment; Jackson Immunores. Lab.), IL-4 20 ng/ml (R&D
Systems), CD40L 20 ng/ml (R&D Systems), LPS 1 lg/ml (Alexis
Biochemicals), BAFF 100 ng/ml (Peprotech), CpG 1 lg/ml
(ODN1668TypB; Source Bioscience), FICZ 250 nM (Enzo Life
Sciences), CH223191 3 lM (Calbiochem), BI605906 10 lM (kindly
provided by S. Ley).
Chromatin immunoprecipitation, RNA extraction, cDNA
generation and real-time RT–PCR
Chromatin immunoprecipitation was performed on 107 cells that
were cross-linked with 1% paraformaldehyde. Chromatin was
isolated upon sequential incubation steps with the following buffers:
buffer 1 (Tris–HCl pH 8 10 mM, EDTA 1 mM, NP40 0.5%, PMSF
1 mM), buffer 2 (Tris–HCl pH 8, EDTA 1 mM, NaCl 0.5 M, Triton
X-100 1%, deoxycholate 0.5%, sarcosyl 0.5%, PMSF 1 mM) and
buffer 3 (Tris–HCl pH 8 10 mM, EDTA 1 mM, NaCl 100 mM,
sarcosyl 0.1%, PMSF 1 mM). Chromatin was then sheared by soni-
cation. 10% of sonicated cell extract was kept as input. Chromatin
was added with RIPA buffer and immunoprecipitated overnight at
4°C with 2 lg of anti-AhR antibody (Enzo Life Sciences, BML-
SA210). Protein G Dynabeads (Life Technologies) were then added
to the cell extract for 3 h at 4°C. Samples were washed 7× in RIPA
wash buffer (added with SDS 0.1%). Crosslinking was reversed in
TE buffer pH 8, SDS 0.5%, proteinase K 200 lg/ml and incubated
overnight at 65°C. DNA was isolated with phenol/chloroform
and analysed by quantitative PCR and by normalization relative
to input DNA amount. The following primers were used for the
Ccno promoter: forward 50-GGGGCTCAGCCAGTGAGA-30; reverse
50-GGCGCAGCTCTAAGTACCC-30.
RNA was extracted using TRIzol Reagent (Life Technologies)
according to manufacturer instructions. RNA to cDNA conversion
was performed using the Omniscript RT kit (Qiagen). Quantification
of target genes was done by quantitative PCR using Taqman
technology (Applied Biosystems). Reaction mixes were run on
the 7900HT Applied Biosystems thermal cycler. TaqMan primer
pairs used to quantify target genes were as follows: Ahr
Mm00478930_m1; Ccno Mm01297259_m1; Cyp1a1
Mm00487217_m1; Hprt1 Mm00446968_m1 (Applied Biosystems).
RNA sequencing analysis
RNA was extracted using the RNAeasy mini kit (Qiagen) and follow-
ing manufacturer instructions. 1 lg RNA was used for further analy-
sis. Library generation was performed according to manufacturer
instructions using the TruSeq stranded mRNA library prep kit (Illu-
mina). Libraries were barcoded and run on an Illumina HiSeq 2000.
The RNAseq data are available in the Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE86521) with accession number GSE86521.
Nuclear/cytoplasmic protein fractionation and Western blot
10–20 × 106 cells were incubated in cytoplasmic lysis buffer (HEPES
pH 7.6 10 mM, EGTA 0.1 mM, KCl 10 mM, MgCl2 1.5 mM, dithio-
threitol 1 mM, NaF 20 mM, protease inhibitor cocktail (Roche),
PMSF 1 mM) for 10 min at 4°C. Detergent NP-40 was added at a
final concentration of 0.2%, and cells were incubated for 1 min on
ice. Supernatant was collected as cytoplasmic protein fraction. The
nuclei pellet was added with nuclear lysis buffer (Tris–HCl pH 7.5
50 mM, NaCl 150 mM, EDTA 2 mM, Triton X-100 1%, dithiothreitol
5 mM, deoxycholate 0.5%, SDS 0.1%, protease inhibitor cocktail,
PMSF 1 mM) and incubated 15 min at 4°C. Supernatant was
collected as nuclear protein fraction.
For Western blot, following antibodies were used: anti-AhR
1:1,000 (Enzo Life Sciences, BML-SA210); anti-Sam68 1:2,000
(Santa Cruz); anti-tubulin 1:2,500 (Sigma); anti-IjBa 1:1,000 (Santa
Cruz); anti-b-actin 1:1,000 (Sigma); anti-Gapdh 1:10,000 (Sigma);
anti-p27kip1 1:200 (R&D Systems); anti-mouse 1:10,000 (GE Health-
care); anti-rabbit 1:10,000 (GE Healthcare).
Enzyme-linked immunoadsorbent assay
Enzyme-linked immunoadsorbent assay (ELISA) to detect anti-TNP,
anti-NP, and anti-Ctx antibodies (Southern Biotech) was performed
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using TNP-BSA 33 lg/ml (Biosearch Technologies), NP-BSA 10 lg/
ml (Biosearch Technologies) and Ctx 10 lg/ml (List Biological Lab.)
as coating.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software.
In case of normally distributed samples, two-group comparison was
done using a two-tailed unpaired t-test, unless in the presence of
paired samples (paired t-test). Comparisons among more than two
groups were analysed with one- or two-way ANOVA, followed by
multiple comparison correction (Dunnett, Sidak or Tukey tests).
Statistical significance is indicated as precise P value.
Expanded View for this article is available online.
Acknowledgements
This work was supported by the Francis Crick Institute, which receives its core
funding from Cancer Research UK, The UK Medical Research Council and the
Wellcome Trust. We would like to acknowledge the animal facility for expert
management of breeding and maintenance of our mice as well as support by
the Flow Cytometry facility and the Sequencing Facility. This work was
funded by a Boehringer Ingelheim Fonds PhD Fellowship to M.V., a Wellcome
Investigator Grant to B.S. and Cancer Research Programme Grant C4639/
A10822 to C.J.H. and C.R.W.
Author contributions
MV performed experiments, analysed data and wrote the manuscript. BS
conceived the study, wrote the manuscript and secured funding. MG and MT
performed specific experiments, and HA performed the bioinformatic analysis
of the RNAseq data. CJH, CRW and RB provided reagents and expert advice.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Baumgarth N (2011) The double life of a B-1 cell: self-reactivity selects for
protective effector functions. Nat Rev Immunol 11: 34 – 46
De Abrew KN, Kaminski NE, Thomas RS (2010) An integrated genomic
analysis of aryl hydrocarbon receptor-mediated inhibition of B-cell
differentiation. Toxicol Sci 118: 454 – 469
Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, Lee KS,
Gonzalez FJ (2000) Altered cell cycle control at the G(2)/M phases in aryl
hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol 57:
1056 – 1063
Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S,
Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ (1995) Immune system
impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah
receptor. Science 268: 722 – 726
Frauenstein K, Sydlik U, Tigges J, Majora M, Wiek C, Hanenberg H, Abel J, Esser C,
Fritsche E, Krutmann J, Haarmann-Stemmann T (2013) Evidence for a novel
anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon
receptor, E2F1, and checkpoint kinase 1. Cell Death Differ 20: 1425–1434
Gitlin AD, Shulman Z, Nussenzweig MC (2014) Clonal selection in the
germinal centre by regulated proliferation and hypermutation. Nature 509:
637 – 640
Hahn ME, Karchner SI, Shapiro MA, Perera SA (1997) Molecular evolution of
two vertebrate aryl hydrocarbon (dioxin) receptors (AHR1 and AHR2) and
the PAS family. Proc Natl Acad Sci USA 94: 13743 – 13748
Henderson CJ, McLaughlin LA, Osuna-Cabello M, Taylor M, Gilbert I, McLaren
AW, Wolf CR (2015) Application of a novel regulatable Cre recombinase
system to define the role of liver and gut metabolism in drug oral
bioavailability. Biochem J 465: 479 – 488
Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M
(2006) Testing gene function early in the B cell lineage in mb1-cre mice.
Proc Natl Acad Sci USA 103: 13789 – 13794
Kerkvliet NI, Steppan LB, Brauner JA, Deyo JA, Henderson MC, Tomar RS,
Buhler DR (1990) Influence of the Ah locus on the humoral
immunotoxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: evidence for
Ah-receptor-dependent and Ah-receptor-independent mechanisms of
immunosuppression. Toxicol Appl Pharmacol 105: 26 – 36
Kerkvliet NI (2002) Recent advances in understanding the mechanisms of
TCDD immunotoxicity. Int Immunopharmacol 2: 277 – 291
Levine-Fridman A, Chen L, Elferink CJ (2004) Cytochrome P4501A1 promotes
G1 phase cell cycle progression by controlling aryl hydrocarbon receptor
activity. Mol Pharmacol 65: 461 – 469
Ma Q, Whitlock JP Jr (1996) The aromatic hydrocarbon receptor modulates
the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin.
Mol Cell Biol 16: 2144 – 2150
Marcus RS, Holsapple MP, Kaminski NE (1998) Lipopolysaccharide activation
of murine splenocytes and splenic B cells increased the expression of aryl
hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator.
J Pharmacol Exp Ther 287: 1113 – 1118
Martin F, Kearney JF (2002) Marginal-zone B cells. Nat Rev Immunol 2:
323 – 335
Mimura J, Yamashita K, Nakamura K, Morita M, Takagi TN, Nakao K, Ema M,
Sogawa K, Yasuda M, Katsuki M, Fujii-Kuriyama Y (1997) Loss of
teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice
lacking the Ah (dioxin) receptor. Genes Cells 2: 645 – 654
Muller SJ, Caradonna S (1991) Isolation and characterization of a human
cDNA encoding uracil-DNA glycosylase. Biochim Biophys Acta 1088:
197 – 207
Muller SJ, Caradonna S (1993) Cell cycle regulation of a human cyclin-like
gene encoding uracil-DNA glycosylase. J Biol Chem 268: 1310 – 1319
Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R (2006) Antigen
recognition strength regulates the choice between extrafollicular plasma
cell and germinal center B cell differentiation. J Exp Med 203: 1081 – 1091
Phan TG, Amesbury M, Gardam S, Crosbie J, Hasbold J, Hodgkin PD, Basten A,
Brink R (2003) B cell receptor-independent stimuli trigger immunoglobulin
(Ig) class switch recombination and production of IgG autoantibodies by
anergic self-reactive B cells. J Exp Med 197: 845 – 860
Pollenz RS, Santostefano MJ, Klett E, Richardson VM, Necela B, Birnbaum LS
(1998) Female Sprague-Dawley rats exposed to a single oral dose of
2,3,7,8-tetrachlorodibenzo-p-dioxin exhibit sustained depletion of aryl
hydrocarbon receptor protein in liver, spleen, thymus, and lung. Toxicol Sci
42: 117 – 128
Puga A, Marlowe J, Barnes S, Chang CY, Maier A, Tan Z, Kerzee JK, Chang X,
Strobeck M, Knudsen ES (2002) Role of the aryl hydrocarbon receptor in
cell cycle regulation. Toxicology 181–182: 171 – 177
Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA (1996) Characterization
of a murine Ahr null allele: involvement of the Ah receptor in hepatic
growth and development. Proc Natl Acad Sci USA 93: 6731 – 6736
Sherr DH, Monti S (2013) The role of the aryl hydrocarbon receptor in normal
and malignant B cell development. Semin Immunopathol 35: 705 – 716
The EMBO Journal ª 2016 The Authors
The EMBO Journal AhR controls B-cell proliferation Matteo Villa et al
12
Published online: November 14, 2016 
Stockinger B, Di Meglio P, Gialitakis M, Duarte JH (2014) The aryl hydrocarbon
receptor: multitasking in the immune system. Annu Rev Immunol 32:
403 – 432
Sulentic CE, Kaminski NE (2011) The long winding road toward
understanding the molecular mechanisms for B-cell suppression by
2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 120(Suppl 1): S171 – S191
Tanaka G, Kanaji S, Hirano A, Arima K, Shinagawa A, Goda C, Yasunaga S,
Ikizawa K, Yanagihara Y, Kubo M, Kuriyama-Fujii Y, Sugita Y, Inokuchi A,
Izuhara K (2005) Induction and activation of the aryl hydrocarbon
receptor by IL-4 in B cells. Int Immunol 17: 797 – 805
Tohkin M, Fukuhara M, Elizondo G, Tomita S, Gonzalez FJ (2000) Aryl
hydrocarbon receptor is required for p300-mediated induction of DNA
synthesis by adenovirus E1A. Mol Pharmacol 58: 845 – 851
Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC,
Stockinger B (2008) The aryl hydrocarbon receptor links TH17-
cell-mediated autoimmunity to environmental toxins. Nature 453:
106 – 109
Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B (2009) Natural
agonists for aryl hydrocarbon receptor in culture medium are essential for
optimal differentiation of Th17 T cells. J Exp Med 206: 43 – 49
Victora GD, Schwickert TA, Fooksman DR, Kamphorst AO, Meyer-Hermann M,
Dustin ML, Nussenzweig MC (2010) Germinal center dynamics revealed by
multiphoton microscopy with a photoactivatable fluorescent reporter. Cell
143: 592 – 605
Vogel CF, Khan EM, Leung PS, Gershwin ME, Chang WL, Wu D, Haarmann-
Stemmann T, Hoffmann A, Denison MS (2014) Cross-talk between aryl
hydrocarbon receptor and the inflammatory response: a role for nuclear
factor-kappaB. J Biol Chem 289: 1866 – 1875
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2016 The Authors The EMBO Journal
Matteo Villa et al AhR controls B-cell proliferation The EMBO Journal
13
Published online: November 14, 2016 
